Safe, Effective Chin and Jaw Restoration With VYC-25L Hyaluronic Acid Injectable Gel

BACKGROUNDVYC-25L, a hyaluronic acid soft-tissue filler with lidocaine, is designed to restore and create facial volume in the chin and jaw. OBJECTIVETo evaluate the safety and effectiveness of VYC-25L in subjects with chin retrusion. METHODSAdults with chin retrusion (145°–165° glabella–subnasale–p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Dermatologic surgery 2019-10, Vol.45 (10), p.1294-1303
Hauptverfasser: Ogilvie, Patricia, Sattler, Gerhard, Gaymans, Frodo, Belhaouari, Lakhdar, Weichman, Barry M, Snow, Sean, Chawla, Smita, Abrams, Steve, Schumacher, Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUNDVYC-25L, a hyaluronic acid soft-tissue filler with lidocaine, is designed to restore and create facial volume in the chin and jaw. OBJECTIVETo evaluate the safety and effectiveness of VYC-25L in subjects with chin retrusion. METHODSAdults with chin retrusion (145°–165° glabella–subnasale–pogonion facial angle) were randomized (3:1) to receive VYC-25L in the chin/jaw at study onset (treatment group) or 3 months later (control group). Primary effectiveness end point was mean change in facial angle from baseline at Month 3. Safety assessments included injection site responses (ISRs), recorded in a subject diary, and adverse events (AEs). RESULTSVYC-25L was administered to 119 subjects (treatment groupn = 90; control groupn = 29). Mean change in facial angle from baseline at Month 3 was significantly greater in the treatment versus control group (difference2.51°; p < .0001). Effectiveness was also demonstrated by the proportion of subjects with improved/much improved Global Aesthetic Improvement Scale scores and responses on FACE-Q Satisfaction and Psychological Well-Being Scales. Treatment benefit remained evident at Month 12. Common ISRs were firmness (95.8%), tenderness (95.8%), and swelling (91.6%). No serious treatment-related AEs were reported. CONCLUSIONVYC-25L significantly improved glabella–subnasale–pogonion facial angle and was generally safe and well tolerated.
ISSN:1076-0512
1524-4725
DOI:10.1097/DSS.0000000000001960